Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam

An Open-label, One-sequence Cross-over Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam in Healthy Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00427505

Enrollment

Registered

2007-01-29

Start date

2006-07-31

Completion date

Unknown

Last updated

2009-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Interaction, healthy volunteers, deferasirox, midazolam

Brief summary

This is a study to investigate the pharmacokinetics of deferasirox

Interventions

DRUGDeferasirox

Study design

Allocation

NON_RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Good health * No evidence of iron deficiency * Weight between 50 and 100 kg * Body Mass Index between 19 and 29 kg/m2

Exclusion criteria

* Use of certain drugs, herbal remedies or nutrients Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame
To assess the effect of deferasirox on the pharmacokinetics of midazolam	—

Secondary

Measure	Time frame
Safety assessed by adverse events (AEs)	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026